Age, Biography and Wiki
David G. Maloney is an American businessman and entrepreneur. He is the founder and CEO of Maloney & Company, a private investment firm. He is also the founder and chairman of the Maloney Family Foundation, a philanthropic organization that supports education, health, and social services. Maloney was born on November 25, 1954 in New York City. He attended the University of Pennsylvania, where he earned a Bachelor of Science degree in Economics. He then went on to earn an MBA from the Wharton School of Business. Maloney began his career in the financial services industry, working for several Wall Street firms. In 1989, he founded Maloney & Company, a private investment firm. He has since grown the firm into a successful business, with investments in a variety of industries, including real estate, technology, and media. Maloney is also the founder and chairman of the Maloney Family Foundation, a philanthropic organization that supports education, health, and social services. He is a member of the Council on Foreign Relations and the Economic Club of New York. Maloney is married and has two children. He currently resides in New York City.
| Popular As | N/A |
| Occupation | N/A |
| Age | 69 years old |
| Zodiac Sign | Sagittarius |
| Born | 25 November, 1954 |
| Birthday | 25 November |
| Birthplace | N/A |
| Nationality |
We recommend you to check the complete list of Famous People born on 25 November. He is a member of famous with the age 69 years old group.
David G. Maloney Height, Weight & Measurements
At 69 years old, David G. Maloney height not available right now. We will update David G. Maloney's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status | |
|---|---|
| Height | Not Available |
| Weight | Not Available |
| Body Measurements | Not Available |
| Eye Color | Not Available |
| Hair Color | Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family | |
|---|---|
| Parents | Not Available |
| Wife | Not Available |
| Sibling | Not Available |
| Children | Not Available |
David G. Maloney Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is David G. Maloney worth at the age of 69 years old? David G. Maloney’s income source is mostly from being a successful . He is from . We have estimated David G. Maloney's net worth , money, salary, income, and assets.
| Net Worth in 2023 | $1 Million - $5 Million |
| Salary in 2023 | Under Review |
| Net Worth in 2022 | Pending |
| Salary in 2022 | Under Review |
| House | Not Available |
| Cars | Not Available |
| Source of Income |
David G. Maloney Social Network
Timeline
Maloney was part of the team that first demonstrated the potential of monoclonal antibodies as cancer therapeutics. He led the initial clinical trials of the drug that resulted from the team’s research, later known as rituximab, which demonstrated its safety and activity against CD20-positive B cells in patients with lymphoma. In 1997, rituximab became the first monoclonal antibody drug for cancer on the market, revolutionizing treatment for B-cell non-Hodgkin lymphoma. Further research by Maloney has continued to develop antibody-based therapeutic strategies for blood cancers.
Building on his expertise with antibody-based cancer therapy and reduced-toxicity treatment approaches, Maloney is developing adoptive T cell therapy for cancer using chimeric antigen receptors, or CARs, synthetic versions of T-cell receptors that incorporate cancer-targeting antibodies, which allow the immune cells to specifically target cancer cells. Maloney leads an early-phase clinical trial for patients with certain advanced, treatment-resistant CD19-positive B-cell cancers, in which patients’ CD4+ and CD8+ T cells are genetically engineered to express a CD19-specific CAR. Preliminary results point toward high rates of remission after CAR T-cell infusion.
Turtle, C.J., Hanafi, L. A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G. (2016). Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine, 8(355), 355ra116.
Turtle, C., Riddell, S. & Maloney, D. (2016). CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies. Clinical Pharmacology & Therapeutics, 100: 252–258. doi:10.1002/cpt.392
Turtle, C. J., & Maloney, D. G. (2016). Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape. Expert Review of Hematology, 719-721.
Vaughn, J. E., Sorror, M. L., Storer, B. E., Chauncey, T. R., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., Hari, P., Laport, G. G., Franke, G. N., Agura, E. D., Langston, A. A., Rezvani, A. R., Storb, R., Sandmaier, B. M. & Maloney, D. G. (2015), Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer, 121: 3709–3716.
Bensinger, W., Rotta, M., Storer, B., Chauncey, T., Holmberg, L., Becker, P., Sandmaier, B. M., Storb, R., & Maloney, D. (2012). Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplantation, 47, 1312-1317.
Burroughs, L. M., O'Donnell, P. V,. Sandmaier, B. M., Storer, B. E., Luznik, L., Symons, H. J., Jones, R. J., Ambinder, R. F., Maris, M. B., Blume, K. G., Niederwieser, D. W., Bruno, B., Maziarz, R. T., Pulsipher, M. A., Petersen, F. B., Storb, R., Fuchs, E. J., Maloney, D.G. (2008). Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 14(11), 1279-1287.
Maloney, D. G., Smith, B., & Rose, A. (2005). Rituximab: mechanism of action and resistance. Seminars in Oncology, 29(1 supp2), 2-9.
Maloney, D. G. (2005). Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. Journal of Clinical Oncology, 10, 6421-6428.
Maloney, D. G. (2003). Graft-vs.-leukemia effect in various histologies of non-Hodgkin's lymphoma. Leukemia & Lymphoma, 44(sup3), S99-S105.
Maloney, D. G., Molina, A. J., Sahebi, F., Stockerl-Goldstein, K. E., Sandmaier, B. M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., Bruno, B., Appelbaum, F. R., Blume, K. G., Forman, S. J., McSweeney, P., & Storb, R. (2003).Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 102(9), 3447-3454.
Storek, J., Joseph, A., Espino, G., Dawson, M. A., Douek, D. C., Sullivan, K. M., Flowers, M. E., Martin, P., Mathioudakis, G., Nash, R. A., Storb, R., Appelbaum, F. R., & Maloney, D. G. (2001). Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood, 98(13), 3505-3512.
Storek, J., Wells, D., Dawson, M. A., Storer, B., & Maloney, D. G. (2001). Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood, 98(2), 489-491.
Maloney, D. G., Donovan, K., & Hamblin, T. J. (1999). Antibody therapy for treatment of multiple myeloma. Seminars in Hematology, 36(1 Suppl 3):30-33.
Maloney, D. G. (1999). Preclinical and phase I and II trials of rituximab. Seminars in Oncology, 26(5 Suppl 14): 74-78.
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997). Journal of Clinical Oncology, 15(10), 3266-3274.
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T., Dallaire, B. K., Wey, K., Royston, I., Davis, T., & Levy, R. (1997). IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. Blood, 90(6), 2188-2195.
Maloney joined the faculties of Fred Hutchinson Cancer Research Center and the University of Washington, both in Seattle, Washington, in 1994.
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994). Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84(8), 2457-2466.
Maloney was named Young Investigator Presidential Award from the International Society for Biological Therapy of Cancer (now the Society for Immunotherapy of Cancer) in 1993. He has been included several times in the Castle Connolly Guides, “America’s Top Doctors” and “America’s Top Doctors for Cancer”, and was named the first Leonard and Norma Klorfine Endowed Chair for Clinical Research at Fred Hutch in 2016.
Miller RA, Maloney DG, Warnke, R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, The New England Journal of Medicine, 309, 517-552.
Maloney earned his Bachelor of Science in chemistry and biochemistry 1977 from Whitworth University in Spokane, Washington. He earned an M.D. from Stanford University in 1985 and a Ph.D. from Stanford in 1991. As a medical student at Stanford, Maloney was a member of the lab of Ronald Levy. He completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in oncology at Stanford University Medical Center.
David G. Maloney (born 25 November 1954) is an oncologist and researcher at Fred Hutchinson Cancer Research Center and the University of Washington who specializes in developing targeted immunotherapies for the treatment of blood cancers.
